199 related articles for article (PubMed ID: 34663255)
1. Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies.
Hao J; Zhou W; Zhang M; Yu H; Zhang T; An R; Xue Y
BMC Cancer; 2021 Oct; 21(1):1122. PubMed ID: 34663255
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
Li J; Li S; Yu H; Wang J; Xu C; Lu X
Gynecol Oncol; 2018 Feb; 148(2):247-253. PubMed ID: 29203174
[TBL] [Abstract][Full Text] [Related]
3. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
Baptista AM; Belfort P
Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Kang HL; Zhao Q; Yang SL; Duan W
Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
[TBL] [Abstract][Full Text] [Related]
5. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
[TBL] [Abstract][Full Text] [Related]
6. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
[TBL] [Abstract][Full Text] [Related]
7. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
[TBL] [Abstract][Full Text] [Related]
8. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R; Lawrie TA
Cochrane Database Syst Rev; 2012 Jul; 7(7):CD007102. PubMed ID: 22786502
[TBL] [Abstract][Full Text] [Related]
9. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities.
Matsui H; Iitsuka Y; Seki K; Sekiya S
Gynecol Obstet Invest; 1998; 46(1):5-8. PubMed ID: 9692333
[TBL] [Abstract][Full Text] [Related]
10. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.
Yarandi F; Mousavi A; Abbaslu F; Aminimoghaddam S; Nekuie S; Adabi K; Hanjani P
Int J Gynecol Cancer; 2016 Jun; 26(5):971-6. PubMed ID: 27101581
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Lertkhachonsuk AA; Hanvoravongchai P
J Reprod Med; 2016; 61(5-6):230-4. PubMed ID: 27424364
[TBL] [Abstract][Full Text] [Related]
12. Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0-4): study protocol for a prospective, multicentre, randomized trial.
Jiang F; Mao MY; Xiang Y; Lu X; Guan CL; Jiao LZ; Wan XR; Feng FZ; Ren T; Yang JJ; Zhao J
BMC Cancer; 2023 Aug; 23(1):784. PubMed ID: 37612621
[TBL] [Abstract][Full Text] [Related]
13. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.
Schink JC; Filiaci V; Huang HQ; Tidy J; Winter M; Carter J; Anderson N; Moxley K; Yabuno A; Taylor SE; Kushnir C; Horowitz N; Miller DS
Gynecol Oncol; 2020 Aug; 158(2):354-360. PubMed ID: 32460997
[TBL] [Abstract][Full Text] [Related]
14. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
Deng L; Zhang J; Wu T; Lawrie TA
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
17. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
[TBL] [Abstract][Full Text] [Related]
19. First line chemotherapy in low risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2009 Jan; (1):CD007102. PubMed ID: 19160319
[TBL] [Abstract][Full Text] [Related]
20. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
